MEOI and HRQoL in CLL patients treated with BTKis

Study identifier:D8220R00036

ClinicalTrials.gov identifier:NCT04938141

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment with Bruton’s Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib

Medical condition

Chronic Lymphocytic Leukemia

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

23

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 07 Oct 2021
Estimated Primary Completion Date: 05 Sept 2024
Estimated Study Completion Date: 05 Sept 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria